



## **Sol-Gel Technologies Ltd. Availability of Its Annual Report on Form 20-F Through Its Website**

March 26, 2018

NESS ZIONA, Israel, March 26, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ:SLGL), a clinical-stage dermatology company, announced today that it filed its Annual Report for 2017 on Form 20-F, containing audited financial statements for the year ended December 31, 2017, as filed with the Securities and Exchange Commission on March 26, 2018, which is available on its website (<http://www.sol-gel.com>). Shareholders may receive a hard copy of the annual report free of charge upon request.

### **About Sol-Gel Technologies**

Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel's current product candidate pipeline consists of late-stage branded product candidates that leverage our proprietary, silica-based microencapsulation technology platform, and several generic product candidates across multiple indications.

### **For further information, please contact:**

Sol-Gel Contact:

Gilad Mamlok

Chief Financial Officer

+972-8-9313433

Investor Contact:

Patricia L. Bank

Westwicke Partners

+1-415-513-1284

[patti.bank@westwicke.com](mailto:patti.bank@westwicke.com)



Source: Sol-Gel Technologies Ltd.